Medicinal Marijuana and Children with Severe Epilepsy
Recent research found that a liquid form of therapeutic marijuana can provide cure to children with treatment-resistant epilepsy. The said study will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC in late April.
The research team conducted the study by first gathering 213 toddlers and adults with a median age of 11. The participants have 12 types of severe epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. These syndromes cause the patient to experience intellectual impairments and seizures that occur throughout life.
The study subjects were administered with a component of marijuana called cannabidiol, which does not cause psychoactive effects. It comes in a liquid form, and is administered daily per orem for 12 weeks. The participants were well aware that they were given the drug as part of an open-label study to identify the effectiveness and tolerability of the drug.
Throughout the course of the study, the researchers monitored the participants for seizures, taking note of the frequency while taking the drug. It was found that there was an average decrease of 54 percent in seizure episodes among 137 of the participants throughout the study. A decline of 53 percent in the incidence of seizure episodes among the 23 participants with Dravet syndrome have also been noted. The 11 participants with Lennox-Gastaut syndrome experienced an abrupt cessation of muscle tone, as attributed to the 55 percent drop in the frequency of atonic seizure episodes. Conversely, six percent of the participants had to stop taking the medication due to side effects, including drowsiness, diarrhoea, tiredness and loss of appetite.
"So far there have been few formal studies on this marijuana extract," said study author Dr Orrin Devinsky of New York University Langone Comprehensive Epilepsy Center, and a fellow of the American Academy of Neurology. "These results are of great interest, especially for the children and their parents who have been searching for an answer for these debilitating seizures." He notes that the study is still in its early stages, and that the initial findings they gathered should be supported by a wider group of double-blind and placebo-controlled trials to determine the drug’s efficacy.
via: International Business Times
To contact the writer, email rinadoctor00@gmail.com
Popular Posts Last 30 Days
-
The active ingredient in marijuana cuts tumor growth in common lung cancer in half and significantly reduces the ability of the...
-
The Dipper is a unique and multi-functional concentrate vaporizer for portable dabbing and vaping. The innovative Vapor Tip Atomizer is a c...
-
By Tom at Kannaboomers What were once vices are now habits. That’s not just the title of the fourth album from the Doobie...
-
The 14er Joint Tip from Elevate Accessories Whether enjoying a spliff alone or with friends, add an Elevate joint tip to tu...
-
According to a research study published by the University Of New Mexico and Releaf App in the Yale Journal of Biology and Medicine, cann...
-
By Tom at Kannaboomers There’s some question about exactly when ‘old age’ starts, but when you think about it, it’s about 15 years o...
-
Cannabinoids (THC, CBD, etc) and opioids have some important similarities. They are both plant-based medicines, both psychoactive, ...
-
The Little Dipper by Dip Devices Little Dipper is the newest product from Dip Devices and the most affordable. The Little Dipper offers Dip...
-
Camphene, sometimes called comphene, is one of more than 200 terpenes discovered to date in hemp and cannabis. Terpenes are aromatic molecul...
